|Project Title||Principal Investigator||Institution|
|Metabolic biomarkers of autism: Predictive potential and genetic susceptibility||James, Sandra||Arkansas Children's Hospital Research Institute|
|Multiplexed suspension arrays to investigate newborn and childhood blood samples for potential immune biomarkers of autism||Vogt, Robert||Centers for Disease Control and Prevention (CDC)|
|Signatures of gene expression in autism spectrum disorders||Kunkel, Louis||Children's Hospital Boston|
|Electrophysiological, metabolic and behavioral markers of infants at risk||Nelson, Charles||Children's Hospital Boston|
|Social communication phenotype of ASD in the second year||Wetherby, Amy||Florida State University|
|Identifying gastrointestinal (GI) conditions in children with autism spectrum disorders (ASD)||Winter, Harland||Harvard Medical School|
|Identification of lipid biomarkers for autism||Kang, Jing||Massachusetts General Hospital|
|Placental vascular tree as biomarker of autism/ASD risk||Salafia, Carolyn||Research Foundation for Mental Hygiene, Inc.|
|Family/Genetic study of autism||Smith, Christopher||Southwestern Autism Research & Resource Center (SARRC)|
|Oxytocin biology and the social deficits of autism spectrum disorders||Parker, Karen||Stanford University|
|Clinical and gene signatures of ASDs||Lewis, Suzanne||University of British Columbia|
|Infants at risk of autism: A longitudinal study||Ozonoff, Sally||University of California, Davis|
|Infants at risk of autism: A longitudinal study (supplement)||Ozonoff, Sally||University of California, Davis|
|Mitochondria and autism||Wallace, Douglas; Gargus, Jay; Golomb, Beatrice; Haas, Richard; Naviaux, Robert; Barshop, Bruce||University of California, Irvine; University of California, San Diego|
|ACE Center: MRI studies of early brain development in autism||Courchesne, Eric||University of California, San Diego|
|Development of neural pathways in infants at risk for autism spectrum disorders||Dobkins, Karen||University of California, San Diego|
|ACE Center: Administrative Core||Eichenbaum, Howard||University of California, San Diego|
|ACE Center: Integrated Biostatistical and Bioinformatic Analysis Core (IBBAC)||Schork, Nicholas||University of California, San Diego|
|Studying the biology and behavior of autism at 1-year: The Well-Baby Check-Up Approach||Pierce, Karen||University of California, San Diego|
|ACE Center: Clinical Phenotype: Recruitment and Assessment Core||Pierce, Karen||University of California, San Diego|
|The genetic link between autism and structural cerebellar malformations||Millen, Kathleen||University of Chicago|
|Language development and outcome in children with autism (supplement)||Naigles, Letitia||University of Connecticut|
|Language development and outcome in children with autism||Naigles, Letitia||University of Connecticut|
|Abnormal vestibulo-ocular reflexes in autism: A potential endophenotype||White, Keith||University of Florida|
|Pupil size and circadian salivary variations in autism spectrum disorder||Colombo, John||University of Kansas|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Identify behavioral and biological markers that separately, or in combination, accurately identify, before age 2, one or more subtypes of children at risk for developing ASD, and evaluate whether these risk markers or profiles can improve early identification through heightened developmental monitoring and screening by 2014.
IACC Recommended Budget: $33,300,000 over 5 years
|1.L.A. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 40 projects have been supported in this area, but most projects are still in the discovery phase. Identifying reliable early biomarkers has been challenging, but some progress has been made. More work is needed to achieve the full intent of the objective.
Remaining Gaps, Needs, and Opportunities: Remaining research needs include continued discovery of biomarkers, linking biomarkers to treatment response, validation of biomarkers discovered in high risk populations for applicability in the general population, and evaluation of whether these biomarkers translate to improvement in screening and diagnosis real-world settings. There is also a need for biomarkers that are cost-effective.